Molecular structure of AZD 5069, CAS Number: 878385-84-3
AZD 5069 (CAS 878385-84-3)
Alternate Names:
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R,2S)-2,3-dihydroxy-1-methylpropoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
CAS Number:
878385-84-3
Molecular Weight:
476.5
Molecular Formula:
C18H22F2N4O5S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
AZD 5069 (CAS 878385-84-3) References
- Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma. | Watz, H., et al. 2017. Pulm Pharmacol Ther. 45: 121-123. PMID: 28549850
- Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. | Cullberg, M., et al. 2018. Drugs R D. 18: 149-159. PMID: 29856004
- Distinct Spatio-Temporal Dynamics of Tumor-Associated Neutrophils in Small Tumor Lesions. | Sody, S., et al. 2019. Front Immunol. 10: 1419. PMID: 31293583
- Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. | Armstrong, CWD., et al. 2020. NAR Cancer. 2: zcaa012. PMID: 32743555
- CXCR2 Mediates Distinct Neutrophil Behavior in Brain Metastatic Breast Tumor. | Safarulla, S., et al. 2022. Cancers (Basel). 14: PMID: 35158784
- Pharmacological perturbation of CXCL1 signaling alleviates neuropathogenesis in a model of HEVA71 infection. | Gunaseelan, S., et al. 2022. Nat Commun. 13: 890. PMID: 35173169
- Neutrophil-derived cathelicidin promotes cerebral angiogenesis after ischemic stroke. | Xie, W., et al. 2023. J Cereb Blood Flow Metab. 43: 1503-1518. PMID: 37194247
- Gastric cancer mesenchymal stem cells via the CXCR2/HK2/PD-L1 pathway mediate immunosuppression. | Huang, C., et al. 2023. Gastric Cancer. 26: 691-707. PMID: 37300724
- Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. | Guo, C., et al. 2023. Nature. 623: 1053-1061. PMID: 37844613
- CXCR2 perturbation promotes Staphylococcus aureus implant-associated infection. | Akaraphanth, M., et al. 2024. J Med Microbiol. 73: PMID: 38567642
- Cell-specific nanoengineering strategy disrupts tolerogenic signaling from myeloid-derived suppressor cells to invigorate antitumor immunity in pancreatic cancer. | Deshpande, NU., et al. 2024. bioRxiv.. PMID: 38854120
- A microphysiological system reveals neutrophil contact-dependent attenuation of pancreatic tumor progression by CXCR2 inhibition-based immunotherapy. | Shao, S., et al. 2024. Sci Rep. 14: 14142. PMID: 38898176
- Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro. | Coperchini, F., et al. 2024. J Endocrinol Invest.. PMID: 38900374
Inhibitor of:
CA X, CKR-1, CXC motif chemokine ligand (CXCL), GROα, GRO1, IL-8, IL-8RB, and RFRP-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AZD 5069, 5 mg | sc-507447 | 5 mg | $230.00 |